Clinical implications of neuroendocrine differentiation in prostate cancer
نویسندگان
چکیده
منابع مشابه
Neuroendocrine differentiation in prostate cancer.
As any organ in the body human prostate is composed of many different types of cells as well as extracellular components. During prostate development, reciprocal cellular interactions between stromal cells and prostate epithelial cells ultimately lead to the development of a mature prostate. Normal prostate is composed of repeating cellular units that contain stromal and epithelial compartments...
متن کاملNeuroendocrine differentiation of prostate cancer.
Global Objectives: Review recent advances in the identification and diagnosis of current and emerging disease states. Discuss the pathophysiology of various disease states and the multidisciplinary considerations that affect patient care outcomes. Identify recent changes in requirements for accreditation, licensing, and regulatory compliance in across all divisions of pathology. Discuss...
متن کاملNeuroendocrine differentiation of prostate cancer: a review.
Neuroendocrine cells are one of the epithelial populations in the prostate. Neuroendocrine differentiation (NED) has been observed in prostate cancer. In addition to small cell neuroendocrine carcinomas and carcinoid tumors of the prostate, prostatic adenocarcinomas may have NED. The incidence and clinical relevance of NED in prostatic adenocarcinoma is not clearly understood because of conflic...
متن کاملProstate cancer with neuroendocrine differentiation – case report
RATIONALE About 95% of prostate cancers are adenocarcinoamas. Depending on the detection method used, neuroendocrine cells are found in 10% to 100% of prostate cancer specimens. OBJECTIVE A 64-year-old patient was diagnosed in 2006 with adenocarcinoma of the prostate, PSA 4.1 ng/ml, Gleason 6, T3b, positive PSA immunohistochemistry. METHODS AND RESULTS The patient was started on hormone the...
متن کاملInduction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
Prostate cancer (PCa) remains the second-leading cause of cancer-related deaths in American men with an estimated mortality of more than 26,000 in 2016 alone. Aggressive and metastatic tumors are treated with androgen deprivation therapies (ADT); however, the tumors acquire resistance and develop into lethal castration resistant prostate cancer (CRPC). With the advent of better therapeutics, th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prostate Cancer and Prostatic Diseases
سال: 2006
ISSN: 1365-7852,1476-5608
DOI: 10.1038/sj.pcan.4500922